The findings that human DBP and E2F8 are also respectively upregulated and downregulated by TGF-β plus IL-4 stimulation and act as enhancer and suppressor to human TH9 differentiation reveals previously unrecognized targets for the investigation of TH9-mediated diseases and tumor immunotherapy in human patients. Here, E2F8 is linked to neoplasm.